(Q33390447)

English

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours (English)

1 reference

Europe PubMed Central

26 July 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Morten Mau-Sorensen

object named as

M Sorensen

3

0 references

object named as

U Lassen

1

0 references

author name string

L R Molife

2

1 reference

Europe PubMed Central

26 July 2017

S-A Engelholm

4

1 reference

Europe PubMed Central

26 July 2017

L Vidal

5

1 reference

Europe PubMed Central

26 July 2017

R Sinha

6

1 reference

Europe PubMed Central

26 July 2017

R T Penson

7

1 reference

Europe PubMed Central

26 July 2017

P Buhl-Jensen

8

1 reference

Europe PubMed Central

26 July 2017

E Crowley

9

1 reference

Europe PubMed Central

26 July 2017

J Tjornelund

10

1 reference

Europe PubMed Central

26 July 2017

P Knoblauch

11

1 reference

Europe PubMed Central

26 July 2017

J S de Bono

12

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

15 June 2010

1 reference

Europe PubMed Central

26 July 2017

British Journal of Cancer

1 reference

Europe PubMed Central

26 July 2017

103

1 reference

Europe PubMed Central

26 July 2017

1

1 reference

Europe PubMed Central

26 July 2017

12-17

1 reference

Europe PubMed Central

26 July 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605726

0 references

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905291

21 June 2018

Histone deacetylase inhibitors that target tubulin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905291

21 June 2018

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905291

21 June 2018

Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905291

21 June 2018

Anticancer activities of histone deacetylase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905291

21 June 2018

Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905291

21 June 2018

In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905291

21 June 2018

Histone deacetylase inhibitors: discovery and development as anticancer agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905291

21 June 2018

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905291

21 June 2018

Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905291

21 June 2018

Histone deacetylases and cancer: causes and therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905291

21 June 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905291

21 June 2018

Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905291

21 June 2018

Histone acetylation in chromatin structure and transcription

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905291

21 June 2018

Letter: Creatinine clearance: bedside estimate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905291

21 June 2018

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905291

21 June 2018

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605726

21 January 2018

Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605726

21 January 2018

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605726

21 January 2018

Clinical pharmacokinetics of carboplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/20588278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20588278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20588278

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6605726

1 reference

Europe PubMed Central

26 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33390447&oldid=1568158937"